Variants and unusual patterns of prostate cancer: Clinicopathologic and differential diagnostic considerations

Advances in Anatomic Pathology

Volumn 19, Issue 4, 2012, Pages 204-216

  Fine, Samson W ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

ductal; foamy pseudohyperplastic; intraductal; mucinous; neuroendocrine; pattern; prostate; squamous; variant

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ANDROGEN DEPRIVATION THERAPY; ATROPHIC CARCINOMA; BASALOID CARCINOMA; CANCER CLASSIFICATION; CANCER HORMONE THERAPY; CARCINOID; CLINICAL FEATURE; DIAGNOSTIC ACCURACY; DIAGNOSTIC ERROR; DIFFERENTIAL DIAGNOSIS; FOAMY GLAND CARCINOMA; GLEASON SCORE; HISTOPATHOLOGY; HUMAN; MUCINOUS CARCINOMA; NEUROENDOCRINE TUMOR; NEUROSECRETORY CELL; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROSTATE CANCER; PROSTATE CARCINOID TUMOR; PROSTATE DUCTAL CARCINOMA; PSEUDOHYPERPLASTIC CARCINOMA; REVIEW; SARCOMATOID CARCINOMA; SIGNET RING CARCINOMA; SQUAMOUS CELL CARCINOMA; TUMOR DIFFERENTIATION;

ADENOCARCINOMA; ADENOCARCINOMA, MUCINOUS; CARCINOMA, DUCTAL; CARCINOMA, NEUROENDOCRINE; CARCINOMA, SIGNET RING CELL; CARCINOMA, SQUAMOUS CELL; DIAGNOSIS, DIFFERENTIAL; HUMANS; MALE; PROSTATE; PROSTATIC NEOPLASMS;

EID: 84862544685     PISSN: 10724109     EISSN: 15334031     Source Type: Journal    
DOI: 10.1097/PAP.0b013e31825c6b92     Document Type: Review

References (154)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics 2012. CA Cancer J Clin. 2012;62:10-29
2. Zaloudek C, Williams JW, Kempson RL. Endometrial adenocarcinoma of the prostate: a distinctive tumor of probable prostatic duct origin. Cancer. 1976;37:2255-2262
3. Bostwick DG, Kindrachuk RW, Rouse RV. Prostatic adenocarcinoma with endometrioid features: clinical, pathologic, and ultrastructural findings. Am J Surg Pathol. 1985; 9:595-609
4. Epstein JI, Woodruff JM. Adenocarcinoma of the prostate with endometrioid features: a light microscopic and immunohistochemical study of ten cases. Cancer. 1986;57:111-119
5. Ro JY, Ayala AG, Wishnow KI, et al. Prostatic duct adenocarcinoma with endometrioid features: immunohistochemical and electron microscopic study. Semin Diagn Pathol. 1988;5:301-311
6. Millar EK, Sharma NK, Lessells AM. Ductal (endometrioid) adenocarcinoma of the prostate: a clinicopathologic study of 16 cases. Histopathology. 1996;29:11-19
7. Dube VE, Farrow GM, Greene LF. Prostatic adenocarcinoma of ductal origin. Cancer. 1973;32:402-409
8. Brinker DA, Potter SR, Epstein JI. Ductal adenocarcinoma of the prostate diagnosed on needle biopsy: correlation with clinical and radical prostatectomy findings and progression. Am J Surg Pathol. 1999;23:1471-1479
9. Greene LF, Farrow GM, Ravits JM, et al. Prostatic adenocarcinoma of ductal origin. J Urol. 1979;121:303-305
10. Colpaert C, Gentens P, Van Marck E. Ductal (endometrioid) adenocarcinoma of the prostate. Acta Urol Belg. 1998;66:29-32
11. Melicow MM, Tannenbaum M. Endometrial carcinoma of the uterus masculinis (prostatic utricle): report of 6 cases. J Urol. 1971;106:892-902
12. Hameed O, Humphrey PA. Stratified epithelium in prostatic adenocarcinoma: a mimic of high-grade prostatic intraepithelial neoplasia. Mod Pathol. 2006;19:899-906
13. Tavora F, Epstein JI. High-grade prostatic intraepithelial neoplasia-like ductal adenocarcinoma of the prostate: a clinicopathologic study of 28 cases. Am J Surg Pathol. 2008;32: 1060-1067
14. Lee TK, Miller JS, Epstein JI. Rare histopathologic patterns of prostatic ductal adenocarcinoma. Pathology. 2010;42:319-324
15. Epstein JI. Prostatic duct adenocarcinoma. In: Epstein JI, Yang XJ, eds. Prostate biopsy interpretation, 3rd edition. Philadelphia: Lippincott Williams & Wilkins; 2002:185-197
16. Bock BJ, Bostwick DG. Does prostatic ductal adenocarcinoma exist? Am J Surg Pathol. 1999;23:781-785
17. Christensen WN, Steinberg WN, Walsh PC, et al. Prostatic duct adenocarcinoma: findings at radical prostatectomy. Cancer. 1991;67:2118-2124
18. Samaratunga H, Duffy D, Yaxley J, et al. Any proportion of ductal adenocarcinoma in radical prostatectomy specimens predicts extraprostatic extension. Hum Pathol. 2010;41:281-285
19. Humphrey PA. Gleason scoring in unusual situations. In: Amin MB, Grignon DJ, Humphrey PA, et al, eds. Gleason grading of prostate cancer: a contemporary approach. Philadelphia: Lippincott Williams & Wilkins; 2004:60-61
20. Epstein JI, Allsbrook WC Jr., Amin MB, et al. The 2005 International Society of Urological Pathology (ISUP) consensus conference on Gleason grading of prostatic carcinoma. Am J Surg Pathol. 2005;29:1228-1242
21. Eade TN, Al-Saleem T, Horwitz EM, et al. Role of radiotherapy in ductal (endometrioid) carcinoma of the prostate. Cancer. 2007;109:2011-2015
22. Gong Y, Caraway N, Stewart J, et al. Metastatic ductal adenocarcinoma of the prostate: cytologic features and clinical findings. Am J Clin Pathol. 2006;126:302-309
23. Herawi M, Epstein JI. Immunohistochemical antibody cocktail staining (p63/HMWCK/AMACR) of ductal adenocarcinoma and Gleason pattern 4 cribriform and noncribriform acinar adenocarcinomas of the prostate. Am J Surg Pathol. 2007;31:889-894
24. Fetisoff F, Duboid WP, Arbeille-Brassart B, et al. Endocrine cells in the prostate gland, urothelium, and Brenner tumors. Virchows Arch B Cell Pathol. 1983;42:53-64
25. Azzopardi JG, Evans DJ. Argentaffin cells in prostatic carcinoma: differentiation from lipofuscin and melanin in prostatic epithelium. J Pathol. 1971;104:247-251
26. di Sant'Agnese PA, de Mesy Jensen KL. Human prostatic endocrine-paracrine (APUD) cells: distributional analysis with a comparison of serotonin and neuron-specific enolase immunoreactivity and silver stains. Arch Pathol Lab Med. 1985;109:607-612
27. Abrahamsson PA. Neuroendocrine differentiation in prostatic carcinoma. Prostate. 1999;39:135-148
28. di Sant'Agnese PA. Neuroendocrine differentiation and prostatic carcinoma: the concept comes of age. Arch Pathol Lab Med. 1988;112:1097-1099
29. Abrahamsson PA, Falkmer S, Falt K, et al. The course of neuroendocrine differentiation in prostatic carcinomas: an immunohistochemical study testing chromogranin A as an endocrine marker. Pathol Res Pract. 1989;185:373-380
30. Cohen RJ, Glezerson G, Haffajee Z. Neuro-endocrine cells: new prognostic parameter in prostate cancer. Br J Urol. 1991;68:258-262
31. Weinstein MH, Partin AW, Veltri RW, et al. Neuroendocrine differentiation in prostate cancer: enhanced prediction of progression after radical prostatectomy. Hum Pathol. 1996; 27:683-687
32. Abrahamsson PA, Cockett ATK, di Sant'Agnese PA. Prognostic significance of neuroendocrine differentiation in clinically localized prostatic carcinoma. Prostate. 1998; 8(SUPPL.):37-42
33. Aprikian AG, Cordon-Cardo C, Fair WR, et al. Neuroendocrine differentiation in metastatic prostatic adenocarcinoma. J Urol. 1994;151:914-919
34. McWilliam LJ, Manson C, George NJR. Neuroendocrine differentiation and prognosis in prostatic adenocarcinomas. Br J Urol. 1997;80:287-290
35. Aprikian AG, Cordon-Cardo C, FairWR, et al. Characterization of neuroendocrine differentiation in human benign prostate and prostatic adenocarcinoma. Cancer. 1993;71:3952-3965
36. Bonkhoff H, Stein U, Remberger K. Androgen receptor status in endocrine-paracrine cell types of normal, hyperplastic, and neoplastic human prostate. Virchows Arch A Pathol Anat Histopathol. 1993;423:291-294
37. Krijnen JL, Janssen PJ, Ruizeveld de Winter JA, et al. Do neuroendocrine cells in human prostate cancer express androgen receptor. Histochemistry. 1993;100:393-398
38. Huang J, Yao JL, di Sant'Agnese PA, et al. Immunohistochemical characterization of neuroendocrine cells in prostate cancer. Prostate. 2006;66:1399-1406
39. Krijnen JL, Bogdanowicz JF, Seldenrijk CA, et al. The prognostic value of neuroendocrine differentiation in adenocarcinoma of the prostate in relation to progression of disease after endocrine therapy. J Urol. 1997;158:171-174
40. Weaver MG, Abdul-Karim FW, Srigley J, et al. Paneth celllike change of the prostate gland: a histological, immunohistochemical, and electron microscopic study. Am J Surg Pathol. 1992;16:62-68
41. Tamas EF, Epstein JI. Prognostic significance of Paneth celllike neuroendocrine differentiation in adenocarcinoma of the prostate. Am J Surg Pathol. 2006;30:980-985
42. Almagro UA. Argyrophilic prostatic carcinoma: case report with literature review on prostatic carcinoid and carcinoidlike prostatic carcinoma. Cancer. 1985;55:608-614
43. Azumi N, Shibuya H, Ishikura M. Primary prostatic carcinoid tumor with intracytoplasmic prostatic acid phosphatase and prostate specific antigen. Am J Surg Pathol. 1984;8:545-550
44. Ghali VS, Garcia RL. Prostatic adenocarcinoma with carcinoidal features producing adrenocorticotropic syn-drome: immunohistochemical study and review of the literature. Cancer. 1984;54:1043-1048
45. Ghannoum JE, DeLellis RA, Shin SJ. Primary carcinoid tumor of the prostate with concurrent adenocarcinoma: a case report. Int J Surg Pathol. 2004;12:167-170
46. Sobin LH, Hjermstad BM, Sesterhenn IA, et al. Prostatic acid phosphatase activity in carcinoid tumors. Cancer. 1986;58: 136-138
47. Stratton M, Evans DJ, Lampert IA. Prostatic adenocarcinoma evolving into carcinoid: selective effect of hormonal treatment? J Clin Pathol. 1986;39:750-756
48. Reyes A, Moran CA. Low-grade neuroendocrine carcinoma (carcinoid tumor) of the prostate. Arch Pathol Lab Med. 2004;128:e166-e168
49. Wenk RE, Bhagavan BS, Levy R, et al. Ectopic ACTH, prostatic oat cell carcinoma, and marked hypernatremia. Cancer. 1977;40:773-778
50. di Sant'Agnese PA. Neuroendocrine differentiation in carcinoma of the prostate: diagnostic, prognostic, and therapeutic implications. Cancer. 1992;70(SUPPL.):254-268
51. Galanis E, Frytak S, Lloyd RV. Extrapulmonary small cell carcinoma. Cancer. 1997;79:1729-1736
52. Matzkin H, Breaf Z. Paraneoplastic syndromes associated with prostatic carcinoma. J Urol. 1987;138:1129-1133
53. Evans AJ, Humphrey PA, Belani J, et al. Large cell neuroendocrine carcinoma of the prostate: a clinicopathologic summary of 7 cases of a rare manifestation of advanced prostate cancer. Am J Surg Pathol. 2006;30:684-693
54. Tetu B, Ro JY, Ayala AG, et al. Small cell carcinoma of the prostate. I. A clinicopathologic study of 20 cases. Cancer. 1987;59:1803-1809
55. Hailemariam S, Gaspert A, Komminoth P, et al. Primary, pure, large-cell neuroendocrine carcinoma of the urinary bladder. Mod Pathol. 1998;11:1016-1020
56. Grignon DJ, Ro JY, Ayala AG, et al. Small cell carcinoma of the urinary bladder: a clinicopathologic analysis of 22 cases. Cancer. 1992;69:527-536
57. Christopher ME, Seftel AD, Sorenson K, et al. Small cell carcinoma of the genitourinary tract: an immunohistochemical, electron microscopic, and clinicopathological study. J Urol. 1991;146:382-388
58. Mills SE, Wolfe JT III, Weiss MA, et al. Small cell undifferentiated carcinoma of the urinary bladder: a lightmicroscopic, immunocytochemical, and ultrastructural study of 12 cases. Am J Surg Pathol. 1987;11:606-617
59. Folpe AL, Gown AM, Lamps LW, et al. Thyroid transcription factor-1: immunohistochemical evaluation in pulmonary neuroendocrine tumors. Mod Pathol. 1999;12:5-8
60. Ordonez NG. Value of thyroid transcription factor-1 immunostaining in distinguishing small cell lung carcinomas from other small cell carcinomas. Am J Surg Pathol. 2000;24:1217-1223
61. Agoff SN, Lamps LW, Philip AT, et al. Thyroid transcription factor-1 is expressed in extrapulmonary small cell carcinomas but not in other extrapulmonary neuroendocrine tumors. Mod Pathol. 2000;13:238-242
62. Yao JL, Madeb R, Bourne P, et al. Small cell carcinoma of the prostate: an immunohistochemical study. Am J Surg Pathol. 2006;30:705-712
63. Ro JY, Tetu B, Ayala AG, et al. Small cell carcinoma of the prostate. II. Immunohistochemical and electron microscopic studies of 18 cases. Cancer. 1987;59:977-982
64. Bonkhoff H, Stein U, Remberger K. Multidirectional differentiation in the normal, hyperplastic, and neoplastic human prostate: simultaneous demonstration of cell-specific epithelial markers. Hum Pathol. 1994;25:42-46
65. Noordzij MA, van der Kwast TH, van Steenbrugge GJ, et al. The prognostic influence of neuroendocrine cells in prostate cancer: results of a long-term follow-up study of patients treated by radical prostatectomy. Int J Cancer. 1995;62: 252-258
66. Schron DS, Gipson T, Mendelsohn G. The histogenesis of small cell carcinoma of the prostate: an immunohistochemical study. Cancer. 1984;53:2478-2480
67. Amato RJ, Logothetis CJ, Hallinan R, et al. Chemotherapy for small cell carcinoma of prostatic origin. J Urol. 1992; 147:935-937
68. Rubinstein JH, Katin MJ, Mangano MM, et al. Small cell anaplastic carcinoma of the prostate: seven new cases, review of the literature, and discussion of a therapeutic strategy. Am J Clin Oncol. 1997;20:376-380
69. Papandreou CN, Daliani DD, Thall PF, et al. Results of a phase II study with doxorubicin, etoposide, and cisplatin in patients with fully characterized small-cell carcinoma of the prostate. J Clin Oncol. 2002;20:3072-3080
70. Murray N, Salgia R, Fossella FV. Targeted molecules in small cell lung cancer. Semin Oncol. 2004;31:106-111
71. Wernert N, Goebbels R, Bonkhoff H, et al. Squamous cell carcinoma of the prostate. Histopathology. 1990;17:339-344
72. Mott LJ. Squamous cell carcinoma of the prostate: report of 2 cases and review of the literature. J Urol. 1979;121:833-835
73. Little NA, Wiener JS, Walther PJ, et al. Squamous cell carcinoma of the prostate: 2 cases of a rare malignancy and review of the literature. J Urol. 1993;149:137-139
74. Miller VA, Reuter V, Scher HI. Primary squamous cell carcinoma of the prostate after radiation seed implantation for adenocarcinoma. Urology. 1995;46:111-113
75. Nabi G, Ansari MS, Singh I, et al. Primary squamous cell carcinoma of the prostate: a rare clinicopathological entity- report of 2 cases and review of literature. Urol Int. 2001; 66:216-219
76. Parwani AV, Kronz JD, Genega EM, et al. Prostate carcinoma with squamous differentiation: an analysis of 33 cases. Am J Surg Pathol. 2004;28:651-657
77. Braslis KG, Davi RC, Nelson E, et al. Squamous cell carcinoma of the prostate: a transformation from adenocarcinoma after the use of a luteinizing hormone-releasing hormone agonist and flutamide. Urology. 1995;45:329-331
78. Accetta PA, Gardner WA Jr. Adenosquamous carcinoma of prostate. Urology. 1983;22:73-75
79. Moyana TN. Adenosquamous carcinoma of the prostate. Am J Surg Pathol. 1987;1:403-407
80. Sieracki JC. Epidermoid carcinoma of the human prostate: report of three cases. Lab Invest. 1955;4:232-240
81. Kahler JE. Carcinoma of the prostate gland: a pathologic study. J Urol. 1939;41:557-574
82. Al Adnani MS. Schistosomiasis, metaplasia and squamous cell carcinoma of the prostate: histogenesis of the squamous cancer cells determined by localization of specific markers. Neoplasma. 1985;32:613-622
83. Baydar DE, Kosemehmetoglu K, Akdogan B, et al. Prostatic adenosquamous carcinoma metastasizing to testis. Scientific-WorldJournal. 2006;6:2491-2494
84. Ishigooka M, Yaguchi H, Tomaru M, et al. Mixed prostatic carcinoma containing malignant squamous elements. Scand J Urol Nephrol. 1994;28:425-427
85. Uchibayashi T, Hisazumi H, Hasegawa M, et al. Squamous cell carcinoma of the prostate. Scand J Urol Nephrol. 1996;31:223-224
86. Okada E, Kamizaki H. Primary squamous cell carcinoma of the prostate. Int J Urol. 2000;7:347-350
87. Majeed F, Javed TA, Khan AU, et al. Primary squamous cell carcinoma of the prostate: a novel chemotherapeutic regimen. J Urol. 2002;168:640
88. Ordonez NG, Ayala AG, von Eschenbach AC, et al. Immunoperoxidase localization of prostatic acid phosphatase in prostatic carcinoma with sarcomatoid changes. Urology. 1982;19:210-214
89. Wick MR, Young RH, Malvesta R, et al. Prostatic carcinosarcomas: clinical, histologic, and immunohistochemical data on two cases with a review of the literature. Am J Clin Pathol. 1989;92:131-139
90. Mostofi FK, Price EB Jr. Malignant tumors of the prostate. In: Mostofi FK, Price EB Jr, eds. Tumors of the Male Genital System. Atlas of Tumor Pathology 2nd Series, Fascicle 8. Washington: Armed Forces Institute of Pathology; 1973:257
91. Epstein JI, Algaba F, Allsbrook WC Jr, et al. Acinar adenocarcinoma. In: Eble JN, Sauter G, Epstein JI, et al, eds. World Health Organization Classification of Tumours: Tumours of the Urinary System and Male Genital Organs. Lyon: IARC Press; 2004:178
92. Shannon RL, Ro JY, Grignon DJ, et al. Sarcomatoid carcinoma of the prostate. Cancer. 1992;69:2676-2682
93. Dundore PA, Cheville JC, Nascimento AG, et al. Carcinosarcoma of the prostate: report of 21 cases. Cancer. 1995;76:1035-1042
94. Hansel DE, Epstein JI. Sarcomatoid carcinoma of the prostate: a study of 42 cases. Am J Surg Pathol. 2006;30: 1316-1321
95. Tsuzkui T, Magi-Galuzzi C, Epstein JI. ALK-1 expression in inflammatory myofibroblastic tumor of the urinary bladder. Am J Surg Pathol. 2004;28:1609-1614
96. Lauwers GY, Schevchuk M, Armenakas N, et al. Carcinosarcoma of the prostate. Am J Surg Pathol. 1993;17:342-349
97. Epstein JI, Armas OA. Atypical basal cell hyperplasia of the prostate. Am J Surg Pathol. 1992;16:1205-1214
98. Grignon DJ, Ro JY, Ordonez NG, et al. Basal cell hyperplasia, adenoid basal cell tumor, and adenoid cystic carcinoma of the prostate: an immunohistochemical study. Hum Pathol. 1988;19:1425-1433
99. Ali TZ, Epstein JI. Basal cell carcinoma of the prostate: a clinicopathologic study of 29 cases. Am J Surg Pathol. 2007;31:697-705
100. Begnami MD, Quezado M, Pinto P, et al. Adenoid cystic/ basal cell carcinoma of the prostate: review and update. Arch Pathol Lab Med. 2007;131:637-640
101. Iczkowski KA, Ferguson KL, Grier DD. Adenoid cystic/ basal cell carcinoma of the prostate: clinicopathologic findings in 19 cases. Am J Surg Pathol. 2003;27:1523-1529
102. McKenney JK, Amin MB, Srigley JR, et al. Basal cell proliferations of the prostate other than usual basal cell hyperplasia: a clinicopathologic study of 23 cases, including four carcinomas, with a proposed classification. Am J Surg Pathol. 2004;28:1289-1298
103. Tan PH, Billis A. Basal cell carcinoma. In: Eble JN, Sauter G, Epstein JI, et al, eds. World Health Organization Classification of Tumours: Tumours of the Urinary System and Male Genital Organs. Lyon: IARC Press; 2004:206
104. Srigley JR, Dardick I, Hartwick RW, et al. Basal epithelial cells of human prostate gland are not myoepithelial cells: a comparative immunohistochemical and ultrastructural study with the human salivary gland. Am J Pathol. 1990;136: 957-966
105. Devaraj LT, Bostwick DG. Atypical basal cell hyperplasia of the prostate: immunophenotypic profile and proposed classification of basal cell proliferations. Am J Surg Pathol. 1993;17:645-659
106. Gleason DF. Atypical hyperplasia and well-differentiated carcinoma of the prostate. Am J Surg Pathol. 1985;9:53-67
107. Young RH, Frierson HF, Mills SE, et al. Adenoid cystic-like tumor of the prostate gland: a report of two cases and review of the literature on 'adenoid cystic carcinoma' of the prostate. Am J Clin Pathol. 1988;89:49-56
108. Yang XJ, McEntee M, Epstein JI. Distinction of basaloid carcinoma of the prostate from benign basal cell lesions by using immunohistochemistry for bcl-2 and Ki-67. Hum Pathol. 1998;28:1447-1450
109. Franks LM, O'Shea JD, Thomson AER. Mucin in the prostate: a histochemical study in normal glands, latent, clinical, and colloid cancers. Cancer. 1964;17:983-991
110. Epstein JI, Lieberman PH. Mucinous adenocarcinoma of the prostate gland. Am J Surg Pathol. 1985;9:299-308
111. Ro JY, Grignon DJ, Ayala AG, et al. Mucinous adenocarcinoma of the prostate: histochemical and immunohistochemical studies. Hum Pathol. 1990;21:593-600
112. Lane BR, Magi-Galluzzi C, Reuther AM, et al. Mucinous adenocarcinoma of the prostate does not confer poor prognosis. Urology. 2006;68:825-830
113. Elbadawi A, Craig W, Linke CA, et al. Prostatic mucinous carcinoma. Urology. 1975;13:658-666
114. Baisden BL, Kahane H, Epstein JI. Perineural invasion, mucinous fibroplasias, and glomerulations: diagnostic features of limited cancer on prostate needle biopsy. Am J Surg Pathol. 1999;23:918-924
115. Osunkoya AO, Nielsen ME, Epstein JI. Prognosis of mucinous adenocarcinoma of the prostate treated by radical prostatectomy: a study of 47 cases. Am J Surg Pathol. 2008;32:468-472
116. Manne RK, Haddad FS. Mucinous adenocarcinoma of the prostate. Urology. 1989;33:247-249
117. Teichman JMH, Shabaik A, Demby AM. Mucinous adenocarcinoma of the prostate and hormone sensitivity. J Urol. 1994;151:701-702
118. Olivas TP, Brady TW. Mucinous adenocarcinoma of the prostate: a report of a case of long-term survival. Urology. 1996;47:256-258
119. Rhee AC, Olgac S, Ohori M, et al. Mucinous adenocarcinoma of the prostate: a case report of long-term disease-free survival and a review of the literature. Urology. 2004; 63:779.e1-779.e2
120. Tran KP, Epstein JI. Mucinous adenocarcinoma of urinary bladder type arising from the prostatic urethra: distinction from mucinous adenocarcinoma of the prostate. Am J Surg Pathol. 1996;20:1346-1350
121. Bismar TA, Humphrey PA, Grignon DG, et al. Expression of b-catenin in prostatic adenocarcinomas: a comparison with colorectal adenocarcinomas. Am J Clin Pathol. 2004;121: 557-563
122. Gaudin PB, Zelefsky MB, Leibel SA. Histopathologic effects of three-dimensional conformal external beam radiation therapy on benign and malignant prostate tissues. Am J Surg Pathol. 1999;23:1021-1031
123. Giltman LI. Signet ring adenocarcinoma of the prostate. J Urol. 1981;126:134-135
124. Ro JY, El-Naggar A, Ayala AG, et al. Signet-ring-cell carcinoma of the prostate: electron-microscopic and immunohistochemical studies of eight cases. Am J Surg Pathol. 1988;12:453-460
125. Hejka AG, England DM. Signet ring cell carcinoma of prostate: immunohistochemical and ultrastructural study of a case. Urology. 1989;24:155-158
126. Torbenson M, Dhir R, Nangia A, et al. Prostatic carcinoma with signet ring cells: a clinicopathologic and immunohistochemical analysis of 12 cases with review of the literature. Mod Pathol. 1998;11:552-559
127. Saito S, Iwaki H. Mucin-producing carcinoma of the prostate: review of 88 cases. Urology. 1999;54:141-144
128. Alline KM, Cohen MB. Signet-ring cell carcinoma of the prostate. Arch Pathol Lab Med. 1992;116:99-102
129. Remmele W, Weber A, Harding P. Primary signet-ring cell carcinoma of the prostate. Hum Pathol. 1988;19: 478-480
130. Catton PA, Hartwick RWJ, Srigley JR. Prostate cancer presenting with malignant ascites: signet ring cell variant of prostatic adenocarcinoma. Urology. 1992;39:495-497
131. Segawa T, Kakehi Y. Primary signet-ring cell adenocarcinoma of the prostate: a case report and literature review. Acta Urol Jpn. 1993;39:565-568
132. Gumus E, Yilmaz B, Miroglu C. Prostate mucinous adenocarcinoma with signet ring cell. Int J Urol. 2003;10:239-241
133. Feiner HD, Gonzalez R. Carcinoma of the prostate with atypical immunohistological features: clinical and histologic correlates. Am J Surg Pathol. 1986;10:765-770
134. Alguacil-Garcia A. Artifactual changes mimicking signet ring cell carcinoma in transurethral prostatectomy specimens. Am J Surg Pathol. 1986;10:795-800
135. Schned AR. Artifactual signet ring cells. Am J Surg Pathol. 1987;11:736-737
136. Armas OA, Aprikian AG, Melamed J, et al. Clinical and pathobiological effects of neoadjuvant total androgen ablation therapy on clinically localized prostatic adenocarcinoma. Am J Surg Pathol. 1994;18:979-991
137. Cina SJ, Epstein JI. Adenocarcinoma of the prostate with atrophic features. Am J Surg Pathol. 1997;21:289-295
138. Egan AJM, Lopez-Beltran A, Bostwick DG. Prostatic adenocarcinoma with atrophic features: malignancy mimicking a benign process. Am J Surg Pathol. 1997;21:931-935
139. Farinola M, Epstein JI. Utility of immunohistochemistry for a-methylacyl-CoA racemase in distinguishing atrophic prostate cancer from benign atrophy. Hum Pathol. 2004;35: 1272-1278
140. Nelson RS, Epstein JI. Prostatic carcinoma with abundant xanthomatous cytoplasm: foamy gland carcinoma. Am J Surg Pathol. 1996;20:419-426
141. Hudson J, Cao D, Vollmer R, et al. Foamy gland adenocarcinoma of the prostate: incidence, Gleason grade, and early clinical outcome. Hum Pathol. 2012. [Epub ahead of print]
142. Tran TT, Sengupta E, Yang XJ. Prostatic foamy gland carcinoma with aggressive behavior: clinicopathologic, immunohistochemical, and ultrastructural analysis. Am J Surg Pathol. 2001;25:618-623
143. Chuang AY, Epstein JI. Xanthoma of the prostate: a mimicker of high-grade prostatic adenocarcinoma. Am J Surg Pathol. 2007;31:1225-1230
144. Zhou M, Jiang Z, Epstein JI. Expression and diagnostic utility of alpha-methylacyl-CoA-racemase in foamy gland and pseudohyperplastic prostate cancer. Am J Surg Pathol. 2003;772-778
145. Muir EG. Carcinoma of the prostate. Lancet. 1934;1:667-672
146. Humphrey PA, Kaleem Z, Swanson PE, et al. Pseudohyperplastic prostatic adenocarcinoma. Am J Surg Pathol. 1998;22:1239-1246
147. Yaskiv O, Cao D, Humphey PA. Microcystic adenocarcinoma of the prostate: a variant of pseudohyperplastic and atrophic patterns. Am J Surg Pathol. 2010;34:556-561
148. Levi AW, Epstein JI. Pseudohyperplastic prostatic adenocarcinoma on needle biopsy and simple prostatectomy. Am J Surg Pathol. 2000;24:1039-1046
149. Arista-Nasr J, Martinez-Benitez B, Valdes S, et al. Pseudohyperplastic prostatic adenocarcinoma in transurethral resections of the prostate. Pathol Oncol Res. 2003;9:232-235
150. Beach R, Gown AM, de Peralta-Venturina MN, et al. P504S immunohistochemical detection in 405 prostatic specimens including 376 18-gauge needle biopsies. Am J Surg Pathol. 2002;26:1588-1596
151. McNeal JE, Redwine EA, Freiha FS, et al. Zonal distribution of prostatic adenocarcinoma: correlation with histologic pattern and direction of spread. Am J Surg Pathol. 1988; 12:897-906
152. Grignon DJ, Sakr WA. Zonal origin of prostatic adenocarcinoma: are there biologic differences between transition zone and peripheral zone adenocarcinomas of the prostate gland? J Cell Biochem SUPPL.. 1994;19:267-269
153. McNeal JE. Cancer volume and site of origin of adenocarcinoma in the prostate: relationship to local and distant spread. Hum Pathol. 1992;23:258-266
154. McNeal JE, Cohen RJ, Brooks JD. Role of cytologic criteria in the histologic diagnosis of Gleason grade 1 prostatic adenocarcinoma. Hum Pathol. 2001;32:441-446